Tolerance to diethylcarbamazine-medicated salt in individuals infected with Onchocerca volvulus.
Identifieur interne : 004934 ( PubMed/Curation ); précédent : 004933; suivant : 004935Tolerance to diethylcarbamazine-medicated salt in individuals infected with Onchocerca volvulus.
Auteurs : D W Meyrowitsch [Danemark] ; P E Simonsen ; P. MagnussenSource :
- Transactions of the Royal Society of Tropical Medicine and Hygiene [ 0035-9203 ]
Descripteurs français
- KwdFr :
- Adulte, Animaux, Chlorure de sodium alimentaire, Diéthylcarbamazine (administration et posologie), Diéthylcarbamazine (effets indésirables), Filaricides (administration et posologie), Filaricides (effets indésirables), Filariose lymphatique (), Humains, Mâle, Méthode en double aveugle, Onchocerca volvulus, Onchocercose (), Onchocercose (traitement médicamenteux), Prurit (), Toxidermies (étiologie).
- MESH :
- administration et posologie : Diéthylcarbamazine, Filaricides.
- effets indésirables : Diéthylcarbamazine, Filaricides.
- traitement médicamenteux : Onchocercose.
- étiologie : Toxidermies.
- Adulte, Animaux, Chlorure de sodium alimentaire, Filariose lymphatique, Humains, Mâle, Méthode en double aveugle, Onchocerca volvulus, Onchocercose, Prurit.
English descriptors
- KwdEn :
- Adult, Animals, Diethylcarbamazine (administration & dosage), Diethylcarbamazine (adverse effects), Double-Blind Method, Drug Eruptions (etiology), Elephantiasis, Filarial (complications), Filaricides (administration & dosage), Filaricides (adverse effects), Humans, Male, Onchocerca volvulus, Onchocerciasis (complications), Onchocerciasis (drug therapy), Pruritus (chemically induced), Sodium Chloride, Dietary.
- MESH :
- chemical , administration & dosage : Diethylcarbamazine, Filaricides.
- chemical , adverse effects : Diethylcarbamazine, Filaricides.
- chemically induced : Pruritus.
- complications : Elephantiasis, Filarial, Onchocerciasis.
- drug therapy : Onchocerciasis.
- etiology : Drug Eruptions.
- Adult, Animals, Double-Blind Method, Humans, Male, Onchocerca volvulus, Sodium Chloride, Dietary.
Abstract
The tolerance of Onchocerca volvulus-infected individuals to diethylcarbamazine (DEC)-medicated salt (0.33% w/w) was assessed in 1996 in Tanzania in a double-blind placebo-controlled hospital-based trial involving 4 groups, each of 10 adult males. Groups I and II had O. volvulus microfilariae (mf) only, group III had both O. volvulus and Wuchereria bancrofti mf, and group IV had W. bancrofti mf only. Groups I, III and IV received DEC-medicated salt, whereas group II was a control to group I and received normal cooking salt. Medication was given for 10 days. The most pronounced adverse reactions in groups I and III were mild-to-moderate itching and rash, beginning after 3-4 days and lasting for the remaining medication period. The reactions did not interfere with normal daily activities. By 20 days after the end of medication, adverse reactions had disappeared in all individuals. The low daily dose of DEC had no significant effect on the O. volvulus pre-medication mf geometric mean intensities (GMIs). In contrast, the medication significantly reduced the pre-medication W. bancrofti mf GMIs. The prospects for using DEC-medicated salt for control of bancroftian filariasis in areas where incidental infections with O. volvulus occur are discussed.
PubMed: 11127254
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004934
Links to Exploration step
pubmed:11127254Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tolerance to diethylcarbamazine-medicated salt in individuals infected with Onchocerca volvulus.</title><author><name sortKey="Meyrowitsch, D W" sort="Meyrowitsch, D W" uniqKey="Meyrowitsch D" first="D W" last="Meyrowitsch">D W Meyrowitsch</name><affiliation wicri:level="1"><nlm:affiliation>Danish Bilharziasis Laboratory, Jaegersborg Alle 1 D, 2920 Charlottenlund, Denmark. fildan@inet.uni2.dk</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Danish Bilharziasis Laboratory, Jaegersborg Alle 1 D, 2920 Charlottenlund</wicri:regionArea></affiliation></author><author><name sortKey="Simonsen, P E" sort="Simonsen, P E" uniqKey="Simonsen P" first="P E" last="Simonsen">P E Simonsen</name></author><author><name sortKey="Magnussen, P" sort="Magnussen, P" uniqKey="Magnussen P" first="P" last="Magnussen">P. Magnussen</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2000 Jul-Aug</MedlineDate></PubDate></date><idno type="RBID">pubmed:11127254</idno><idno type="pmid">11127254</idno><idno type="wicri:Area/PubMed/Corpus">004934</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">004934</idno><idno type="wicri:Area/PubMed/Curation">004934</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">004934</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Tolerance to diethylcarbamazine-medicated salt in individuals infected with Onchocerca volvulus.</title><author><name sortKey="Meyrowitsch, D W" sort="Meyrowitsch, D W" uniqKey="Meyrowitsch D" first="D W" last="Meyrowitsch">D W Meyrowitsch</name><affiliation wicri:level="1"><nlm:affiliation>Danish Bilharziasis Laboratory, Jaegersborg Alle 1 D, 2920 Charlottenlund, Denmark. fildan@inet.uni2.dk</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>Danish Bilharziasis Laboratory, Jaegersborg Alle 1 D, 2920 Charlottenlund</wicri:regionArea></affiliation></author><author><name sortKey="Simonsen, P E" sort="Simonsen, P E" uniqKey="Simonsen P" first="P E" last="Simonsen">P E Simonsen</name></author><author><name sortKey="Magnussen, P" sort="Magnussen, P" uniqKey="Magnussen P" first="P" last="Magnussen">P. Magnussen</name></author></analytic><series><title level="j">Transactions of the Royal Society of Tropical Medicine and Hygiene</title><idno type="ISSN">0035-9203</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Animals</term><term>Diethylcarbamazine (administration & dosage)</term><term>Diethylcarbamazine (adverse effects)</term><term>Double-Blind Method</term><term>Drug Eruptions (etiology)</term><term>Elephantiasis, Filarial (complications)</term><term>Filaricides (administration & dosage)</term><term>Filaricides (adverse effects)</term><term>Humans</term><term>Male</term><term>Onchocerca volvulus</term><term>Onchocerciasis (complications)</term><term>Onchocerciasis (drug therapy)</term><term>Pruritus (chemically induced)</term><term>Sodium Chloride, Dietary</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Animaux</term><term>Chlorure de sodium alimentaire</term><term>Diéthylcarbamazine (administration et posologie)</term><term>Diéthylcarbamazine (effets indésirables)</term><term>Filaricides (administration et posologie)</term><term>Filaricides (effets indésirables)</term><term>Filariose lymphatique ()</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Onchocerca volvulus</term><term>Onchocercose ()</term><term>Onchocercose (traitement médicamenteux)</term><term>Prurit ()</term><term>Toxidermies (étiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Diéthylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Pruritus</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Elephantiasis, Filarial</term><term>Onchocerciasis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Onchocerciasis</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Diéthylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Drug Eruptions</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Onchocercose</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Toxidermies</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Animals</term><term>Double-Blind Method</term><term>Humans</term><term>Male</term><term>Onchocerca volvulus</term><term>Sodium Chloride, Dietary</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Animaux</term><term>Chlorure de sodium alimentaire</term><term>Filariose lymphatique</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Onchocerca volvulus</term><term>Onchocercose</term><term>Prurit</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The tolerance of Onchocerca volvulus-infected individuals to diethylcarbamazine (DEC)-medicated salt (0.33% w/w) was assessed in 1996 in Tanzania in a double-blind placebo-controlled hospital-based trial involving 4 groups, each of 10 adult males. Groups I and II had O. volvulus microfilariae (mf) only, group III had both O. volvulus and Wuchereria bancrofti mf, and group IV had W. bancrofti mf only. Groups I, III and IV received DEC-medicated salt, whereas group II was a control to group I and received normal cooking salt. Medication was given for 10 days. The most pronounced adverse reactions in groups I and III were mild-to-moderate itching and rash, beginning after 3-4 days and lasting for the remaining medication period. The reactions did not interfere with normal daily activities. By 20 days after the end of medication, adverse reactions had disappeared in all individuals. The low daily dose of DEC had no significant effect on the O. volvulus pre-medication mf geometric mean intensities (GMIs). In contrast, the medication significantly reduced the pre-medication W. bancrofti mf GMIs. The prospects for using DEC-medicated salt for control of bancroftian filariasis in areas where incidental infections with O. volvulus occur are discussed.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11127254</PMID><DateCreated><Year>2000</Year><Month>12</Month><Day>13</Day></DateCreated><DateCompleted><Year>2001</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0035-9203</ISSN><JournalIssue CitedMedium="Print"><Volume>94</Volume><Issue>4</Issue><PubDate><MedlineDate>2000 Jul-Aug</MedlineDate></PubDate></JournalIssue><Title>Transactions of the Royal Society of Tropical Medicine and Hygiene</Title><ISOAbbreviation>Trans. R. Soc. Trop. Med. Hyg.</ISOAbbreviation></Journal><ArticleTitle>Tolerance to diethylcarbamazine-medicated salt in individuals infected with Onchocerca volvulus.</ArticleTitle><Pagination><MedlinePgn>444-8</MedlinePgn></Pagination><Abstract><AbstractText>The tolerance of Onchocerca volvulus-infected individuals to diethylcarbamazine (DEC)-medicated salt (0.33% w/w) was assessed in 1996 in Tanzania in a double-blind placebo-controlled hospital-based trial involving 4 groups, each of 10 adult males. Groups I and II had O. volvulus microfilariae (mf) only, group III had both O. volvulus and Wuchereria bancrofti mf, and group IV had W. bancrofti mf only. Groups I, III and IV received DEC-medicated salt, whereas group II was a control to group I and received normal cooking salt. Medication was given for 10 days. The most pronounced adverse reactions in groups I and III were mild-to-moderate itching and rash, beginning after 3-4 days and lasting for the remaining medication period. The reactions did not interfere with normal daily activities. By 20 days after the end of medication, adverse reactions had disappeared in all individuals. The low daily dose of DEC had no significant effect on the O. volvulus pre-medication mf geometric mean intensities (GMIs). In contrast, the medication significantly reduced the pre-medication W. bancrofti mf GMIs. The prospects for using DEC-medicated salt for control of bancroftian filariasis in areas where incidental infections with O. volvulus occur are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meyrowitsch</LastName><ForeName>D W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Danish Bilharziasis Laboratory, Jaegersborg Alle 1 D, 2920 Charlottenlund, Denmark. fildan@inet.uni2.dk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simonsen</LastName><ForeName>P E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Magnussen</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trans R Soc Trop Med Hyg</MedlineTA><NlmUniqueID>7506129</NlmUniqueID><ISSNLinking>0035-9203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005369">Filaricides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017673">Sodium Chloride, Dietary</NameOfSubstance></Chemical><Chemical><RegistryNumber>V867Q8X3ZD</RegistryNumber><NameOfSubstance UI="D004049">Diethylcarbamazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004049" MajorTopicYN="N">Diethylcarbamazine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003875" MajorTopicYN="N">Drug Eruptions</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005369" MajorTopicYN="N">Filaricides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017181" MajorTopicYN="Y">Onchocerca volvulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009855" MajorTopicYN="N">Onchocerciasis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011537" MajorTopicYN="N">Pruritus</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017673" MajorTopicYN="N">Sodium Chloride, Dietary</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>12</Month><Day>29</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>3</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>12</Month><Day>29</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11127254</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004934 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 004934 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:11127254
|texte= Tolerance to diethylcarbamazine-medicated salt in individuals infected with Onchocerca volvulus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:11127254" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |